Gynecologic and Obstetric Clinic, Department of Medical, Surgical and Experimental Sciences, University of Sassari, Sassari, Italy; PhD School in Biomedical Sciences, University of Sassari, Sassari, Italy.
Department of Gynecologic Oncology, University of Palermo, Palermo, Italy.
Semin Cancer Biol. 2021 Dec;77:194-202. doi: 10.1016/j.semcancer.2021.02.009. Epub 2021 Feb 16.
In the last decade, a growing attention has been focused on identifying effective therapeutic strategies also in the orphan clinical setting of women with platinum-resistant disease. In this context, secondary cytoreductive surgery (SCS) remains a potential approach only in women with platinum sensitive relapse, but experimental data have been published supporting the role of SCS also in patients with platinum-resistant recurrence. In particular, surgery is emerging as a potential option in specific subgroups of women, such as those patients with low-grade serous histology, or low-volume relapse with disease located in the so-called pharmacological sanctuaries. Furthermore, contrasting evidences have suggested a potential role in this clinical setting of SCS combined with intraperitoneal hyperthermic chemotherapy. In this complex scenario we review here the available evidences regarding the role surgery in ovarian cancer patients with platinum resistant disease, trying also to understand which patients may benefit from this challenging, experimental approach.
在过去的十年中，人们越来越关注在治疗患有铂耐药疾病的女性这一罕见临床情况下确定有效的治疗策略。在这种情况下，二次细胞减灭术（SCS）仍然只是针对铂类敏感复发的女性的一种潜在方法，但已发表的实验数据支持 SCS 在铂类耐药复发患者中的作用。特别是，手术作为一种潜在选择在特定的亚组女性中出现，例如那些具有低级别浆液性组织学或疾病位于所谓的药物避难所的低容量复发的患者。此外，相反的证据表明，SCS 联合腹腔内高温化疗在这种临床情况下可能具有潜在作用。在这种复杂的情况下，我们在这里回顾了关于铂耐药卵巢癌患者手术作用的现有证据，同时也试图了解哪些患者可能受益于这种具有挑战性的实验方法。
